Argenx

Argenx is a biotechnology company that develops and commercializes antibody-based therapies for autoimmune diseases and other conditions.

Why it’s in the news: It is in the news due to the failure of a late-stage study for one of its drugs and a major acquisition.

Latest on Argenx

• STAT+: Pharmalittle: We’re reading about a setback for Argenx, Lilly suits over copycat versions of an obesity drug, and more
• STAT+: Argenx sees unusual setback with failure of late-stage study of drug for autoimmune disease
• STAT+: Argenx to buy Forte Biosciences for $2.2B

Connections

5 entities linked to Argenx across the news graph.